German biotech firm Miltenyi Biotec has announced the opening of its first office in Hyderabad and will set up the Miltenyi Innovation & Technology Centre which will serve as a centre of excellence (CoE) for cell and gene therapy (CGT). The announcement was made at BioAsia 2024, after Chief Minister Revanth Reddy had a meeting with the company's leadership team.

The CoE will offer training on CGT approaches right from proof of concept to pre-clinical and clinical development and commercialization. It will also provide Indian researchers, scientists and clinicians easier access to expertise, research and manufacturing solutions.

The biotech player is well-positioned to enable local development and manufacturing in India to drive affordable and accessible CGT therapies by academia and industry. It is eyeing opportunities to catalyse the development of CAR (chimeric antigen receptor)-T cell clinical development and manufacturing, with the intent to bring centralised and point-of-care CAR-T cell therapy to hospitals across India.

The company is focused on driving accessibility, affordability and availability of cell and gene therapies through local development and manufacturing in India.